key: cord-0328046-325x3gyo
authors: Jeulin, H.; Craus, D.; Labat, C.; Benetos, A.
title: Comparative analysis of post-vaccination anti-spike IgG antibodies in old Nursing Home Residents and in middle-aged Healthcare workers
date: 2021-08-04
journal: nan
DOI: 10.1101/2021.08.03.21261014
sha: 9af963ad6516a0f6841c5b2b1c6f1898a7c37222
doc_id: 328046
cord_uid: 325x3gyo

The current consensus is that 2 doses of mRNA vaccines against SARS-CoV-2 are needed for people without COVID-19 history, while for those who had suffered COVID-19, a single dose may be enough to achieve high levels of immunization. This consensus has been based on results obtained in middle-aged populations, whereas only few data exist for the oldest and most frail adults such as nursing home residents (NH-Res) that is, the population most vulnerable to develop severe forms of COVID-19. In this study, we studied the anti-SARS-CoV-2 IgG(S) level of NH-Res and healthcare workers (HCWs) with or without a history of COVID-19 infection taking into account the time since immunization (COVID-19 and/or vaccination). 654 subjects were analyzed: 397 NH-Res (median age 88, IQR 82-93 years, 75% women) and 257 Health Care Workers (HCWs, median 46, IQR 38-54 years, 81% women). NH-Res and HCWs were classified in one of the following 3 groups: No-COVID history and 2 vaccine shots (COV-NO/2VACC); Yes-COVID history and 1 (COV-YES/1VACC) or 2 (COV-YES/2VACC) vaccine injections. The time-related decrease in IgG (S) in subjects without COVID-19 history, SARS-COV-2 serology would be negative in HCWs approximately 220 days and in residents 180 days after vaccination. This time-related decrease was much slower in those with history of COVID. NH-Res belonging into the COV-NO/2VACC and the COV-YES/1VACC groups showed lower IgG (S) levels than the same groups of HCWs (for both groups, p<0.0001), whereas in the group COV-YES/2VACC, IgG (S) levels were similar in NH-Res and HCWs (p=0.88). These results remained unchanged after adjustment for age and duration since immunization. Thus, in NH-Res, 2 vaccine shots were associated with a more pronounced immune response, whereas in HCWs, 1 or 2 vaccine shots in patients with COVID-19 history did make any difference. These results indicate significant differences in mRNA vaccination between NH-Res and middle-aged controls, and could contribute to the specification of vaccine policy in this very old, frail population.

The current consensus is that 2 doses of mRNA vaccines against SARS-CoV-2 are needed for people without COVID-19 history, while for those who had suffered COVID-19, a single dose may be enough to achieve high levels of immunization. This consensus has been based on results obtained in middle-aged populations, whereas only few data exist for the oldest and most frail adults such as nursing home residents (NH-Res) that is, the population most vulnerable to develop severe forms of COVID-19.

In this study, we studied the anti-SARS-CoV-2 IgG(S) level of NH-Res and healthcare workers NH-Res belonging into the COV-NO/2VACC and the COV-YES/1VACC groups showed lower IgG (S) levels than the same groups of HCWs (for both groups, p<0.0001), whereas in the group COV-YES/2VACC, IgG (S) levels were similar in NH-Res and HCWs (p=0.88). These results remained unchanged after adjustment for age and duration since immunization.

Thus, in NH-Res, 2 vaccine shots were associated with a more pronounced immune response, whereas in HCWs, 1 or 2 vaccine shots in patients with COVID-19 history did make any difference. These results indicate significant differences in mRNA vaccination between NH-Res and middle-aged controls, and could contribute to the specification of vaccine policy in this very old, frail population. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The development of vaccines against SARS-CoV-2, allows the possibility for massive immunization of the population and the control of coronavirus disease 2019 (COVID-19). mRNA vaccines have been used in hundreds of millions of people showing high efficacy and safety profiles (1,2) even in older patients (3) . Several public health and political authorities have raised the question of the number of doses of vaccines required to achieve high levels of immunization. The current consensus is that 2 doses are needed for people without a history of COVID-19, while for those who have suffered COVID-19, a single dose may be enough to reach the level reached by people not infected who received 2 injections (4-6).

These studies were mainly carried out in young and middle-aged populations; there are however few data for the oldest and most frail adults such as residents of nursing homes (NHs) that is, the population most vulnerable to develop severe forms of COVID-19. One recent study by Blain et coll has shown that in NH residents with history of COVID-19, one injection of mRNA vaccine was followed by a significant development of anti-spike IgG (7).

However, no study has assessed the magnitude of the antibody response to mRNA vaccination in very old subjects in comparison to young-middle aged individuals i.e. subjects who showed a very good response to vaccination against SARS-CoV-2.

To this end, we compared the post-vaccination anti-SARS-CoV-2 IgG(S) level in NH Residents (NH-Res) and in healthcare workers (HCWs) with or without a history of COVID-19 infection taking into account the time between the "last immune stimulation" (COVID-19 and/or vaccination) and the moment of the IgG detection.

NH-Res of 10 NHs participating in this study (including the NH of the Geriatric Dpt of the University hospital of Nancy) and HCWs from the same NHs and the Geriatric Dpt of the University hospital of Nancy were included (see list of the participant NHs in the front page).

The current analysis was coordinated by the Geriatric Dpt of the University hospital of Nancy (CHRU de Nancy). The directors and medical coordinators of these centers gave their agreement for the participation to this study. Residents and staff have been informed orally or with posters in the respective health institutions, of the possibility of using their serology results for clinical research purposes. The Ethics Committee of the Nancy CHRU hospital made the statement that this research has been carried out in accordance to current French is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint This study has declared in ClinicaTrials (ClinicalTrials.gov Identifier: NCT04964024).

 A SARS-COV-2 (anti-spike IgG) serology performed between April 1 -July 2, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 4, 2021. ; https://doi.org/10.1101/2021.08.03.21261014 doi: medRxiv preprint were used in the adjusted models. When the ANOVA test was statistically significant, a posthoc Tukey-Kramer's test was used to test the 2 by 2 differences. Multiple regression analyses were also conducted in order to test the role of the number of vaccine injections (1 vs.2) in residents and health professionals with history of COVID-19. Pearson correlation was used to study the association between IgG (S) values and time since immunization in COV-NO/2VACC in NH-Res and in HCWs. A P <0.05 was considered significant.

A total of 654 subjects were included: 397 NH-Res (median age 88, IQR 82-93 years, 75% women) and 257 HCWs (median 46, IQR 38-54 years, 81% women). Table 1 shows the main characteristics of the Covid-19/Vaccine groups in each one of these 2 populations. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 4, 2021. ; https://doi.org/10.1101/2021.08.03.21261014 doi: medRxiv preprint * In the COV-YES / 2VACC group, 32/109 NH-Res and 3/21 HCWs suffered COVID-19 after the 2 vaccine injections. Their IgG (S) antibody levels were similar compared with those of the same subgroups who contracted COVID-19 before the vaccination (2-way ANOVA, p=0.83), which allowed us to regroup them. ** time between last immune stimulation (COVID-19 and/or vaccination) and the anti IgG (S) detection. *** for statistical comparisons see Figure 2 

In non-COVID subjects (both HCWs and NH-Res) time from the 2 nd vaccine injection was negatively associated with the IgG (S) levels ( Figure 1 In HCWs with history of COVID due to the low number of subjects in each subgroup the same analyses were conducted after grouping those with 1 (n=49) or 2 vaccine injections (n=21). This was possible since IgG responses to 1 or 2 injections were not different (see Table 1 and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 4, 2021. ; https://doi.org/10.1101/2021.08.03.21261014 doi: medRxiv preprint p=0.003). In NH-Res with COVID-19 history, grouping those with 1 and 2 vaccine injections was not possible because of the different IgG (S) responses between these 2 subgroups, and therefore analyses were performed separately: In the group COV-YES/2VACC (n=109) the equation was: IgG(S) (AU) = 780 -0.98 X days (R= -0.21, p= 0.03). In the COV-YES/1VACC (n=54) no such relationship was observed (p=0.32).

Age was also a significant determinant of the IgG (S) response (negative relationship) but only in subjects without history of COVID-19 (p<0.01 in HCWs and p=0.02 in NH-Res). No such relationship was observed in subjects with COVID-19 history.

The IgG (S) levels following vaccination are shown in Table 1 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 4, 2021. The role of the 2nd injection in NH-Res and HCWs with COVID history was also studied using a multiple regression analyses (including also in the model, Age and time from the last immune stimulation as independent variables). This analysis showed that the 2 nd vaccine injection dramatically increases IgG (S) in NH-Res by 429 ± 36 AIU (R 2 = 43%, p<0.0001). By contrast, in HCWs, the 2 nd dose did not induce any modification in IgG (S) levels (p=0.23).

In the present study, we evaluated the SARS-CoV-2 IgG(S) antibody response to the vaccination in NHs residents i.e. in a very old (88 years at mean), frail population which is one of the most vulnerable population for having severe forms of COVID-19. Although IgG (S) levels represent just a part of the global immunity response (8) , it has been shown that "compromised immune responses to the SARS-CoV-2 spike is a major trait of COVID-19 patients with critical conditions" (9) . In the present study, the results obtained in the different NH-Res groups were compared with those of middle-aged HCWs with or without a history of COVID-19 infection. This comparison showed lower levels of IgG(S) in the NH-Res is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 4, 2021. ; https://doi.org/10.1101/2021.08.03.21261014 doi: medRxiv preprint population in two groups: COVID-NO/VACC2 and COVID-YES/VACC1. In contrast, in the COVID-NO/VACC2, NH-Res and HCWs showed similar IgG (S) levels, indicating that the second injection of mRNA vaccine, 3 to 6 weeks after the first shot, significantly increased IgG (S) values in the very old frail subjects.

One could ask that in all these groups median IgG (S) values were clearly higher than the threshold of positivity (10-13 AU/ml) and therefore differences among the different groups are clinically not relevant. However, a recent study has shown that only sera with mean IgG (S) level > 126 AU/mL were associated with a neutralizing activity of SARS-CoV-2 on Vero E6 cells (Neutralizing titer 50 ≥ 40) (10) . Therefore, it is reasonable to look for high IgG(S) levels especially in the very old, vulnerable patients. We also analyzed the time-related decrease in IgG (S) in the different subgroups. The obtained results allowed us to make some estimation about the time after vaccination for a serology to become negative. Following this estimation, in subjects without COVID history, IgG (S) levels would be negative in HCWs approximately 220 days and in residents 180 days after vaccination.

For subjects with history of COVID-19, a longer time delay is estimated: about 470 days, from vaccination in HCWs and for NH-Res we did not observe a significant decrease in the IgG level during the follow-up after 2 post-COVID vaccine shots. These results are in accordance with previously described data showing that very old people can elicit durable SARS-CoV-2 spike specific IgG antibodies following COVID infection (11) . However, it is important to define a vaccine strategy in order to obtain sufficient neutralizing antibodies level in order to guarantee a long term sufficient immunization One major limitation of our study is its cross-sectional character and therefore results have is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 4, 2021. ; https://doi.org/10.1101/2021.08.03.21261014 doi: medRxiv preprint to be interpreted with a lot of precaution.

Conclusions: The present results could suggest that in NH-Res residents with a history of COVID, a double vaccination provides the highest IgG (S) levels and therefore the strategy of a single vaccine shot should be reconsidered for this very old frail population. The clinical meaning of our results concerning the time-related decrease in IgG (S) need to be investigated in large longitudinal studies, analyzing the long term post vaccination neutralization capacity and precise the need of a booster vaccine shot.

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Prior COVID-19 Infection and Antibody Response to Single Versus Double Dose mRNA SARS-CoV-2 Vaccination

Surgeon Fills COVID-19 Testing Gap in Philadelphia's Black Neighborhoods

Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival

Evaluation of LIAISON ® SARS CoV 2 TrimericS IgG assay and comparison with microneutralization titers31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

Centenarians and extremely old people living with frailty can elicit durable SARS-CoV-2 spike specific IgG antibodies with virus neutralization functions following virus infection as determined by serological study